Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
71 hedge funds and large institutions have $22.5M invested in Elevation Oncology in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
4% more funds holding
Funds holding: 68 → 71 (+3)
10.1% less ownership
Funds ownership: 77.71% → 67.61% (-10%)
18% less capital invested
Capital invested by funds: $27.6M → $22.5M (-$5.07M)
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$157K |
| 2 |
BlackRock
New York
|
+$152K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$118K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$94.3K |
| 5 |
JP Morgan Chase
New York
|
+$70.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.38M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$815K |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$779K |
| 4 |
Morgan Stanley
New York
|
-$313K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$287K |
ELEV Hedge Fund Activity: Q4 2024 in Review
71 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2024, worth a combined $22.5M — down 18% from $27.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ELEV positions and 11 closed out — a net gain of 3 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $157K. The largest seller was Goldman Sachs, cutting an estimated $1.38M.
- 71 institutional investors held Elevation Oncology (ELEV) as of Q4 2024, up from 68 in Q3 2024.
- Funds reported $22.5M of Elevation Oncology stock for Q4 2024, down 18% quarter-over-quarter.
- 14 funds opened new Elevation Oncology positions in Q4 2024 and 11 closed out, a net change of +3 holders.
- The largest Elevation Oncology buyer in Q4 2024 was Citadel Advisors, an estimated $157K added.
- The largest Elevation Oncology seller in Q4 2024 was Goldman Sachs, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2024.